Solu Therapeutics

Boston, United States

Solu Therapeutics Platform Company that develops antibody-based medicines using a degradable warhead.

$41.0M raised

Apr 2025

Series A

Biotechnology Medical Therapeutics

Top Investors

Eli LillyLongwood FundSante VenturesDCVC BioPappas Capital

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Solu Therapeutics

How much funding has Solu Therapeutics raised?

Solu Therapeutics has raised $41.0M in total funding. The most recent round was Series A. The last funding was announced in April 2025.

Who are Solu Therapeutics's investors?

Solu Therapeutics's investors include Eli Lilly, Longwood Fund, Sante Ventures, DCVC Bio, Pappas Capital.

Where is Solu Therapeutics headquartered?

Solu Therapeutics is headquartered in Boston, United States.

What does Solu Therapeutics do?

Solu Therapeutics Platform Company that develops antibody-based medicines using a degradable warhead.

What stage is Solu Therapeutics at?

Solu Therapeutics is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated April 9, 2025.

MLA

"Solu Therapeutics — Funding & Investors." VCBacked, April 9, 2025, https://www.vcbacked.co/company/solu-therapeutics. Accessed June 9, 2026.

APA

VCBacked. (2025). Solu Therapeutics — Funding & Investors. Retrieved June 9, 2026, from https://www.vcbacked.co/company/solu-therapeutics

Wikipedia (cite web)

{{cite web |title=Solu Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/solu-therapeutics |website=VCBacked |access-date=June 9, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated April 9, 2025.

Similar Companies in Biotechnology